ResMed Inc. $RMD Shares Sold by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. cut its stake in shares of ResMed Inc. (NYSE:RMD) by 66.5% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 1,202 shares of the medical equipment provider’s stock after selling 2,385 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in ResMed were worth $329,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. SJS Investment Consulting Inc. lifted its stake in shares of ResMed by 1,433.3% in the third quarter. SJS Investment Consulting Inc. now owns 92 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 86 shares in the last quarter. WFA of San Diego LLC acquired a new position in ResMed in the second quarter valued at approximately $26,000. GoalVest Advisory LLC acquired a new position in ResMed during the 3rd quarter valued at approximately $37,000. Harbour Investments Inc. boosted its holdings in shares of ResMed by 264.2% during the second quarter. Harbour Investments Inc. now owns 244 shares of the medical equipment provider’s stock valued at $63,000 after acquiring an additional 177 shares during the period. Finally, Root Financial Partners LLC acquired a new position in ResMed during the 3rd quarter valued at about $64,000. Institutional investors and hedge funds own 54.98% of the company’s stock.

ResMed Price Performance

Shares of NYSE:RMD opened at $257.76 on Monday. The company’s fifty day moving average is $251.04 and its two-hundred day moving average is $263.37. The company has a market cap of $37.62 billion, a P/E ratio of 25.50, a price-to-earnings-growth ratio of 1.72 and a beta of 0.87. The company has a quick ratio of 2.32, a current ratio of 3.06 and a debt-to-equity ratio of 0.06. ResMed Inc. has a 12-month low of $199.92 and a 12-month high of $293.81.

ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $2.81 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.13. ResMed had a net margin of 27.53% and a return on equity of 25.20%. The firm had revenue of $1.42 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same period in the previous year, the firm posted $2.43 earnings per share. The firm’s revenue was up 11.0% on a year-over-year basis. Equities analysts expect that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 19th. Stockholders of record on Thursday, February 12th will be issued a dividend of $0.60 per share. The ex-dividend date is Thursday, February 12th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. ResMed’s dividend payout ratio (DPR) is currently 23.74%.

Trending Headlines about ResMed

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Q2 results beat consensus — GAAP diluted EPS of $2.68 (non‑GAAP $2.81) vs. Street estimates ~ $2.68, revenue $1.423B (+11% YoY), 320 bps gross‑margin improvement and $340M operating cash flow. These metrics support near‑term earnings credibility and cash generation. Read More.
• Positive Sentiment: Board declared a quarterly cash dividend of $0.60 per share (record Feb 12; payable Mar 19), signaling capital return commitment and supporting income investors. Read More.
• Positive Sentiment: Product/innovation catalysts: FDA cleared an AI‑enabled device (“Smart Comfort”) to personalize CPAP settings — strengthens digital/AI positioning and could boost adherence and recurring device/accessory demand. Read More.
• Positive Sentiment: Wells Fargo nudged its price target to $270 (from $265) with an “equal weight” rating — a modest analyst lift that implies limited near‑term upside from that shop. Read More.
• Neutral Sentiment: Analyst landscape remains mixed but generally favorable — several firms maintain outperform/buy views and available median targets sit materially above current price, leaving room for differing investor expectations. Read More.
• Neutral Sentiment: Company hosted the Q2 webcast and transcripts are posted — useful for hearing management’s guide/comments on demand, supply and margin outlook. Read More.
• Negative Sentiment: Expenses rose: SG&A and R&D both increased (~12% YoY) and the company recorded $6M in restructuring charges; higher operating costs could pressure margins if growth slows. Read More.
• Negative Sentiment: Notable insider selling activity was reported in recent months (multiple sales by senior executives), which some investors view as a modest governance/conviction caution. Read More.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on RMD shares. Wells Fargo & Company increased their price target on ResMed from $265.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Friday. Citigroup reaffirmed a “buy” rating on shares of ResMed in a report on Monday. Morgan Stanley set a $305.00 target price on shares of ResMed in a research report on Friday, October 31st. Stifel Nicolaus boosted their price target on shares of ResMed from $260.00 to $265.00 and gave the stock a “hold” rating in a research report on Friday. Finally, Robert W. Baird set a $281.00 price target on shares of ResMed in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, ResMed presently has a consensus rating of “Moderate Buy” and a consensus price target of $297.91.

Insider Activity at ResMed

In other ResMed news, CEO Michael J. Farrell sold 4,991 shares of the stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $248.46, for a total transaction of $1,240,063.86. Following the transaction, the chief executive officer directly owned 466,223 shares of the company’s stock, valued at $115,837,766.58. This represents a 1.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $248.83, for a total value of $497,660.00. Following the transaction, the director directly owned 66,773 shares in the company, valued at approximately $16,615,125.59. This represents a 2.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 21,594 shares of company stock valued at $5,403,495. Insiders own 0.65% of the company’s stock.

ResMed Company Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.